Click here to close
Hello! We notice that you are using Internet Explorer, which is not supported by Xenbase and may cause the site to display incorrectly.
We suggest using a current version of Chrome,
FireFox, or Safari.
Biochem Pharmacol
2007 Oct 15;748:1271-82. doi: 10.1016/j.bcp.2007.07.021.
Show Gene links
Show Anatomy links
Discovery of a novel nicotinic receptor antagonist for the treatment of nicotine addiction: 1-(3-Picolinium)-12-triethylammonium-dodecane dibromide (TMPD).
???displayArticle.abstract???
Limitations in efficacy and high relapse rates of currently available smoking cessation agents reveal the need for more efficacious pharmacotherapies. One strategy is to develop subtype-selective nicotinic receptor (nAChR) antagonists that inhibit nicotine-evoked dopamine (DA) release, the primary neurotransmitter involved in nicotine reward. Simple alkylation of the pyridino N-atom converts nicotine from a potent agonist into a potent antagonist. The classical antagonists, hexamethonium and decamethonium, differentiate between peripheral nAChR subtypes. Using a similar approach, we interconnected varying quaternary ammonium moieties with a lipophilic linker to provide N,N'-bis-nicotinium analogs, affording a lead compound, N,N'-dodecyl-1,12-diyl-bis-3-picolinium dibromide (bPiDDB), which inhibited nicotine-evoked DA release and decreased nicotine self-administration. The current work describes a novel compound, 1-(3-picolinium)-12-triethylammonium-dodecane dibromide (TMPD), a hybrid of bPiDDB and decamethonium. TMPD completely inhibited (IC(50)=500 nM) nicotine-evoked DA release from superfused rat striatal slices, suggesting that TMPD acts as a nAChR antagonist at more than one subtype. TMPD (1 microM) inhibited the response to acetylcholine at alpha3beta4, alpha4beta4, alpha4beta2, and alpha1beta1varepsilondelta receptors expressed in Xenopus oocytes. TMPD had a 2-fold higher affinity than choline for the blood-brain barrier choline transporter, suggesting brain bioavailability. TMPD did not inhibit hyperactivity in nicotine sensitized rats, but significantly and specifically decreased nicotine self-administration. Together, the results suggest that TMPD may have the ability to reduce the rewarding effect of nicotine with minimal side effects, a pharmacological profile indicative of potential clinical utility for the treatment of tobacco dependence.
Allen,
Active transport of high-affinity choline and nicotine analogs into the central nervous system by the blood-brain barrier choline transporter.
2003, Pubmed
Allen,
Active transport of high-affinity choline and nicotine analogs into the central nervous system by the blood-brain barrier choline transporter.
2003,
Pubmed Allen,
Characterization of the blood-brain barrier choline transporter using the in situ rat brain perfusion technique.
2001,
Pubmed Anand,
Neuronal nicotinic acetylcholine receptors expressed in Xenopus oocytes have a pentameric quaternary structure.
1991,
Pubmed
,
Xenbase Azam,
Expression of neuronal nicotinic acetylcholine receptor subunit mRNAs within midbrain dopamine neurons.
2002,
Pubmed Balfour,
The neurobiology of tobacco dependence: a commentary.
2002,
Pubmed Champtiaux,
Subunit composition of functional nicotinic receptors in dopaminergic neurons investigated with knock-out mice.
2003,
Pubmed Charpantier,
Nicotinic acetylcholine subunit mRNA expression in dopaminergic neurons of the rat substantia nigra and ventral tegmental area.
1998,
Pubmed Chavez-Noriega,
Pharmacological characterization of recombinant human neuronal nicotinic acetylcholine receptors h alpha 2 beta 2, h alpha 2 beta 4, h alpha 3 beta 2, h alpha 3 beta 4, h alpha 4 beta 2, h alpha 4 beta 4 and h alpha 7 expressed in Xenopus oocytes.
1997,
Pubmed
,
Xenbase Clark,
In silico prediction of blood-brain barrier permeation.
2003,
Pubmed Clarke,
Nicotine and smoking: a perspective from animal studies.
1987,
Pubmed Cooper,
Pentameric structure and subunit stoichiometry of a neuronal nicotinic acetylcholine receptor.
1991,
Pubmed Corrigall,
Self-administered nicotine activates the mesolimbic dopamine system through the ventral tegmental area.
1994,
Pubmed Corrigall,
The mesolimbic dopaminergic system is implicated in the reinforcing effects of nicotine.
1992,
Pubmed Corrigall,
Nicotine maintains robust self-administration in rats on a limited-access schedule.
1989,
Pubmed Corringer,
Nicotine enhances intracellular nicotinic receptor maturation: a novel mechanism of neural plasticity?
2006,
Pubmed Crooks,
Development of subtype-selective ligands as antagonists at nicotinic receptors mediating nicotine-evoked dopamine release.
2004,
Pubmed Cui,
The beta3 nicotinic receptor subunit: a component of alpha-conotoxin MII-binding nicotinic acetylcholine receptors that modulate dopamine release and related behaviors.
2003,
Pubmed Dani,
Nicotinic acetylcholine receptors and nicotinic cholinergic mechanisms of the central nervous system.
2007,
Pubmed Deneris,
Beta 3: a new member of nicotinic acetylcholine receptor gene family is expressed in brain.
1989,
Pubmed Dowell,
Alpha-conotoxin PIA is selective for alpha6 subunit-containing nicotinic acetylcholine receptors.
2003,
Pubmed
,
Xenbase Dwoskin,
Development of a novel class of subtype-selective nicotinic receptor antagonist: pyridine-N-substituted nicotine analogs.
1999,
Pubmed Dwoskin,
Acute and chronic effects of nornicotine on locomotor activity in rats: altered response to nicotine.
1999,
Pubmed Dwoskin,
Competitive neuronal nicotinic receptor antagonists: a new direction for drug discovery.
2001,
Pubmed Dwoskin,
Subtype-selective nicotinic receptor antagonists: potential as tobacco use cessation agents.
2004,
Pubmed George,
Current pharmacological treatments for nicotine dependence.
2004,
Pubmed Göldner,
Immunohistochemical localization of the nicotinic acetylcholine receptor subunit alpha6 to dopaminergic neurons in the substantia nigra and ventral tegmental area.
1997,
Pubmed Gotti,
Neuronal nicotinic receptors: from structure to pathology.
2004,
Pubmed Gotti,
Brain nicotinic acetylcholine receptors: native subtypes and their relevance.
2006,
Pubmed Grady,
Nicotinic agonists stimulate acetylcholine release from mouse interpeduncular nucleus: a function mediated by a different nAChR than dopamine release from striatum.
2001,
Pubmed Grady,
Characterization of nicotinic receptor-mediated [3H]dopamine release from synaptosomes prepared from mouse striatum.
1992,
Pubmed Grady,
Characterization of nicotinic agonist-induced [(3)H]dopamine release from synaptosomes prepared from four mouse brain regions.
2002,
Pubmed Grinevich,
N-n-alkylpyridinium analogs, a novel class of nicotinic receptor antagonists: selective inhibition of nicotine-evoked [3H] dopamine overflow from superfused rat striatal slices.
2003,
Pubmed Grottick,
Evidence that nicotinic alpha(7) receptors are not involved in the hyperlocomotor and rewarding effects of nicotine.
2000,
Pubmed
,
Xenbase Harvey,
Determinants of competitive antagonist sensitivity on neuronal nicotinic receptor beta subunits.
1996,
Pubmed
,
Xenbase Hurt,
Nicotine patch therapy based on smoking rate followed by bupropion for prevention of relapse to smoking.
2003,
Pubmed Kaiser,
Differential inhibition by alpha-conotoxin-MII of the nicotinic stimulation of [3H]dopamine release from rat striatal synaptosomes and slices.
1998,
Pubmed
,
Xenbase Kulak,
Alpha-conotoxin MII blocks nicotine-stimulated dopamine release in rat striatal synaptosomes.
1997,
Pubmed Kuryatov,
Human alpha6 AChR subtypes: subunit composition, assembly, and pharmacological responses.
2000,
Pubmed
,
Xenbase Laviolette,
The neurobiology of nicotine addiction: bridging the gap from molecules to behaviour.
2004,
Pubmed Le Novère,
Neuronal nicotinic receptor alpha 6 subunit mRNA is selectively concentrated in catecholaminergic nuclei of the rat brain.
1996,
Pubmed Le Novère,
Molecular evolution of the nicotinic acetylcholine receptor: an example of multigene family in excitable cells.
1995,
Pubmed Lockman,
Cation transport specificity at the blood-brain barrier.
2004,
Pubmed Lockman,
Nicotine exposure does not alter plasma to brain choline transfer.
2006,
Pubmed Lockman,
The transport of choline.
2002,
Pubmed López-Hernández,
Nicotine-induced up-regulation and desensitization of alpha4beta2 neuronal nicotinic receptors depend on subunit ratio.
2004,
Pubmed
,
Xenbase Luetje,
Getting past the asterisk: the subunit composition of presynaptic nicotinic receptors that modulate striatal dopamine release.
2004,
Pubmed Lukas,
International Union of Pharmacology. XX. Current status of the nomenclature for nicotinic acetylcholine receptors and their subunits.
1999,
Pubmed McCallum,
Increases in alpha4* but not alpha3*/alpha6* nicotinic receptor sites and function in the primate striatum following chronic oral nicotine treatment.
2006,
Pubmed McGehee,
Physiological diversity of nicotinic acetylcholine receptors expressed by vertebrate neurons.
1995,
Pubmed Nelson,
Alternate stoichiometries of alpha4beta2 nicotinic acetylcholine receptors.
2003,
Pubmed
,
Xenbase Neugebauer,
Effect of a novel nicotinic receptor antagonist, N,N'-dodecane-1,12-diyl-bis-3-picolinium dibromide, on nicotine self-administration and hyperactivity in rats.
2006,
Pubmed Papke,
Comparative pharmacology of rat and human alpha7 nAChR conducted with net charge analysis.
2002,
Pubmed
,
Xenbase Papke,
The pharmacological activity of nicotine and nornicotine on nAChRs subtypes: relevance to nicotine dependence and drug discovery.
2007,
Pubmed
,
Xenbase Papke,
The effects of subunit composition on the inhibition of nicotinic receptors by the amphipathic blocker 2,2,6,6-tetramethylpiperidin-4-yl heptanoate.
2005,
Pubmed
,
Xenbase Pardridge,
Drug and gene targeting to the brain with molecular Trojan horses.
2002,
Pubmed Parker,
Neuronal nicotinic receptor beta2 and beta4 subunits confer large differences in agonist binding affinity.
1998,
Pubmed
,
Xenbase Paterson,
The mGluR5 antagonist MPEP decreased nicotine self-administration in rats and mice.
2003,
Pubmed Perry,
Measuring nicotinic receptors with characteristics of alpha4beta2, alpha3beta2 and alpha3beta4 subtypes in rat tissues by autoradiography.
2002,
Pubmed Picciotto,
Acetylcholine receptors containing the beta2 subunit are involved in the reinforcing properties of nicotine.
1998,
Pubmed Pontieri,
Effects of nicotine on the nucleus accumbens and similarity to those of addictive drugs.
1996,
Pubmed Rahman,
The effects of a novel nicotinic receptor antagonist N,N-dodecane-1,12-diyl-bis-3-picolinium dibromide (bPiDDB) on acute and repeated nicotine-induced increases in extracellular dopamine in rat nucleus accumbens.
2007,
Pubmed Rose,
Blockade of smoking satisfaction using the peripheral nicotinic antagonist trimethaphan.
1999,
Pubmed Salminen,
Subunit composition and pharmacology of two classes of striatal presynaptic nicotinic acetylcholine receptors mediating dopamine release in mice.
2004,
Pubmed Samejima,
Representation of action-specific reward values in the striatum.
2005,
Pubmed Schultz,
Getting formal with dopamine and reward.
2002,
Pubmed Smith,
Facilitated transport of the neurotoxin, beta-N-methylamino-L-alanine, across the blood-brain barrier.
1992,
Pubmed Stolerman,
The scientific case that nicotine is addictive.
1995,
Pubmed Sumithran,
Introduction of unsaturation into the N-n-alkyl chain of the nicotinic receptor antagonists, NONI and NDNI: effect on affinity and selectivity.
2005,
Pubmed Teng,
Nicotinic-receptor mediation of S(-)nornicotine-evoked -3H-overflow from rat striatal slices preloaded with -3H-dopamine.
1997,
Pubmed Wada,
Distribution of alpha 2, alpha 3, alpha 4, and beta 2 neuronal nicotinic receptor subunit mRNAs in the central nervous system: a hybridization histochemical study in the rat.
1989,
Pubmed
,
Xenbase Whiteaker,
Pharmacological and null mutation approaches reveal nicotinic receptor diversity.
2000,
Pubmed Wileyto,
Do small lapses predict relapse to smoking behavior under bupropion treatment?
2004,
Pubmed Wilkins,
N-n-alkylnicotinium analogs, a novel class of nicotinic receptor antagonist: inhibition of S(-)-nicotine-evoked [(3)H]dopamine overflow from superfused rat striatal slices.
2002,
Pubmed Wilkins,
N-n-alkylnicotinium analogs, a novel class of nicotinic receptor antagonists: interaction with alpha4beta2* and alpha7* neuronal nicotinic receptors.
2003,
Pubmed
